These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 9106529)
1. The G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia susceptibility in a British pedigree. Adeokun AM; West SP; Ellis FR; Halsall PJ; Hopkins PM; Foroughmand AM; Iles DE; Robinson RL; Stewart AD; Curran JL Am J Hum Genet; 1997 Apr; 60(4):833-41. PubMed ID: 9106529 [TBL] [Abstract][Full Text] [Related]
2. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602 [TBL] [Abstract][Full Text] [Related]
3. RYR mutation G1021A (Gly341Arg) is not frequent in Danish and Swedish families with malignant hyperthermia susceptibility. Fagerlund T; Ording H; Bendixen D; Islander G; Ranklev-Twetman E; Berg K Clin Genet; 1996 Apr; 49(4):186-8. PubMed ID: 8828983 [TBL] [Abstract][Full Text] [Related]
4. Exclusion of defects in the skeletal muscle specific regions of the DHPR alpha 1 subunit as frequent causes of malignant hyperthermia. O'Brien RO; Taske NL; Hansbro PM; Matthaei KI; Hogan SP; Denborough MA; Foster PS J Med Genet; 1995 Nov; 32(11):913-4. PubMed ID: 8592342 [TBL] [Abstract][Full Text] [Related]
5. A simple method to detect the RYR1 mutation G1021A, a cause of malignant hyperthermia susceptibility. Alestrøm A; Fagerlund TH; Berg K Clin Genet; 1995 May; 47(5):274-5. PubMed ID: 7554356 [TBL] [Abstract][Full Text] [Related]
6. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Quane KA; Keating KE; Healy JM; Manning BM; Krivosic-Horber R; Krivosic I; Monnier N; Lunardi J; McCarthy TV Genomics; 1994 Sep; 23(1):236-9. PubMed ID: 7829078 [TBL] [Abstract][Full Text] [Related]
7. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546 [TBL] [Abstract][Full Text] [Related]
8. Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred. Lynch PJ; Krivosic-Horber R; Reyford H; Monnier N; Quane K; Adnet P; Haudecoeur G; Krivosic I; McCarthy T; Lunardi J Anesthesiology; 1997 Mar; 86(3):620-6. PubMed ID: 9066328 [TBL] [Abstract][Full Text] [Related]
9. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response. Steinfath M; Singh S; Scholz J; Becker K; Lenzen C; Wappler F; Köchling A; Roewer N; Schulte am Esch J J Mol Med (Berl); 1995 Jan; 73(1):35-40. PubMed ID: 7633940 [TBL] [Abstract][Full Text] [Related]
11. Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. Keating KE; Quane KA; Manning BM; Lehane M; Hartung E; Censier K; Urwyler A; Klausnitzer M; Muller CR; Heffron JJ Hum Mol Genet; 1994 Oct; 3(10):1855-8. PubMed ID: 7849712 [TBL] [Abstract][Full Text] [Related]
12. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Brandt A; Schleithoff L; Jurkat-Rott K; Klingler W; Baur C; Lehmann-Horn F Hum Mol Genet; 1999 Oct; 8(11):2055-62. PubMed ID: 10484775 [TBL] [Abstract][Full Text] [Related]
13. [In vitro contracture test and gene typing in diagnosing malignant hyperthermia. Each as an appropriate complement to the other method]. Rüffert H; Olthoff D; Deutrich C; Thamm B; Froster U Anaesthesist; 2000 Feb; 49(2):113-20. PubMed ID: 10756965 [TBL] [Abstract][Full Text] [Related]
15. Ryanodine receptor mutations in malignant hyperthermia and central core disease. McCarthy TV; Quane KA; Lynch PJ Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202 [TBL] [Abstract][Full Text] [Related]
16. Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes. Keating KE; Giblin L; Lynch PJ; Quane KA; Lehane M; Heffron JJ; McCarthy TV J Med Genet; 1997 Apr; 34(4):291-6. PubMed ID: 9138151 [TBL] [Abstract][Full Text] [Related]
17. A mutation in the human ryanodine receptor gene associated with central core disease. Zhang Y; Chen HS; Khanna VK; De Leon S; Phillips MS; Schappert K; Britt BA; Browell AK; MacLennan DH Nat Genet; 1993 Sep; 5(1):46-50. PubMed ID: 8220422 [TBL] [Abstract][Full Text] [Related]
18. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Monnier N; Procaccio V; Stieglitz P; Lunardi J Am J Hum Genet; 1997 Jun; 60(6):1316-25. PubMed ID: 9199552 [TBL] [Abstract][Full Text] [Related]
19. Recombination between the postulated CCD/MHE/MHS locus and RYR1 gene markers. Fagerlund TH; Islander G; Ranklev-Twetman E; Berg K Clin Genet; 1996 Dec; 50(6):455-8. PubMed ID: 9147872 [TBL] [Abstract][Full Text] [Related]
20. Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Quane KA; Keating KE; Manning BM; Healy JM; Monsieurs K; Heffron JJ; Lehane M; Heytens L; Krivosic-Horber R; Adnet P Hum Mol Genet; 1994 Mar; 3(3):471-6. PubMed ID: 8012359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]